RESUMEN
Intelligent Prescription Systems (IPS) represent a promising frontier in healthcare, offering the potential to optimize medication selection, dosing, and monitoring tailored to individual patient needs. This comprehensive review explores the current landscape of IPS, encompassing various technological approaches, applications, benefits, and challenges. IPS leverages advanced computational algorithms, machine learning techniques, and big data analytics to analyze patient-specific factors, such as medical history, genetic makeup, biomarkers, and lifestyle variables. By integrating this information with evidence-based guidelines, clinical decision support systems, and real-time patient data, IPS generates personalized treatment recommendations that enhance therapeutic outcomes while minimizing adverse effects and drug interactions. Key components of IPS include predictive modeling, Drug-Drug Interaction detection, adverse event prediction, dose optimization, and medication adherence monitoring. These systems offer clinicians invaluable decision-support tools to navigate the complexities of medication management, particularly in the context of polypharmacy and chronic disease management. While IPS holds immense promise for improving patient care and reducing healthcare costs, several challenges must be addressed. These include data privacy and security concerns, interoperability issues, integration with existing electronic health record systems, and clinician adoption barriers. Additionally, the regulatory landscape surrounding IPS requires clarification to ensure compliance with evolving healthcare regulations. Despite these challenges, the rapid advancements in artificial intelligence, data analytics, and digital health technologies are driving the continued evolution and adoption of IPS. As precision medicine gains momentum, IPS is poised to play a central role in revolutionizing medication management, ultimately leading to more effective, personalized, and patient-centric healthcare delivery.
RESUMEN
Globally, one of the leading causes of cancer-related deaths is colon cancer. As this form of cancer has a tremendous potential to metastasize, effective treatment is complicated and sometimes impossible. Despite the improvement of conventional chemotherapy and the advent of targeted therapies, overcoming multi-drug resistance (MDR) and side effects remain significant challenges. As a therapeutic intervention for targeted gene silencing in cancer, RNA technology shows promise and certain RNA-based formulations are currently undergoing clinical studies. Various studies have reported that RNA-based nanoparticles have demonstrated substantial promise for targeted medication delivery, gene therapy, and other biomedical applications. However, using RNA as a therapeutic tool presents severe limitations, mainly related to its low stability and poor cellular uptake. Nanotechnology offers a flexible and tailored alternative due to the difficulties in delivering naked RNA molecules safely in vivo, such as their short half-lives, low chemical stability, and susceptibility to nuclease degradation. In addition to shielding RNA molecules from immune system attacks and enzymatic breakdown, the nanoparticle-based delivery systems allow RNA accumulation at the tumor site. The potential of RNA and RNA-associated nanomedicines for the treatment of colon cancer, as well as the prospects for overcoming any difficulties related to mRNA, are reviewed in this study, along with the current progress of mRNA therapeutics and advancements in designing nanomaterials and delivery strategies.
RESUMEN
Emerging lipid-based carriers are revolutionizing drug delivery in the pharmaceutical and biomedical sciences. These innovative carriers harness the unique properties of lipids to improve the solubility, stability, and targeted delivery of therapeutic agents, ushering in a new era of precision medicine. Lipid- based carriers, such as liposomes, lipid nanoparticles, and solid lipid nanoparticles, offer several advantages. They can encapsulate both hydrophilic and hydrophobic drugs, enabling the delivery of a wide range of compounds. Additionally, lipids are biocompatible and biodegradable, minimizing the risk of toxicity. Their ability to mimic cell membranes allows for enhanced cellular uptake and controlled release, optimizing drug efficacy while minimizing side effects. Furthermore, lipid-based carriers are ideal for delivering drugs to specific sites within the body. By modifying the lipid composition, surface charge, and size, researchers can tailor these carriers to target tumours, inflamed tissues, or specific cells, improving therapeutic outcomes and reducing systemic toxicity. In summary, emerging lipid-based carriers are poised to transform pharmaceutical and biomedical sciences by addressing critical challenges in drug delivery. These carriers enhance drug stability, bioavailability, and targeted delivery, offering the potential to revolutionize the treatment of various diseases and improve patient outcomes. As research in this field continues to advance, we can expect even more sophisticated lipid-based carrier systems to emerge, further expanding the possibilities for precision medicine. This review focuses on the contribution of lipid carriers in the pharmaceutical and biomedical sciences.